Kelun SKB565 Gets NMPA Nod for Dual-Payload ADC
Decision brief
Answer first · skim in under a minute
Kelun-Biotech said on July 27, 2026 that NMPA CDE cleared an IND for SKB565, its first dual-payload ADC for advanced solid tumors.
Kelun SKB565 NMPA IND dual-payload ADC clearance moves the company's first toxin-plus-immunomodulator conjugate into the clinic. On July 27, 2026, Kelun-Biotech said China's Center for Drug Evaluation approved the investigational new drug application for advanced solid tumors.
Contents10 sections
Key Takeaways
- NMPA CDE issued a clinical trial notice for SKB565 on July 27, 2026.
- SKB565 is Kelun-Biotech's first dual-payload ADC to enter clinical development.
- The OptiDC design pairs a cytotoxic toxin with an immunomodulator payload.
- Preclinical antitumor activity and safety were cited; human efficacy is unproven.
SKB565 IND at a glance
| Field | Detail |
|---|---|
| Candidate | SKB565 |
| Sponsor | Sichuan Kelun-Biotech Biopharmaceutical (6990.HK) |
| Platform | OptiDC dual-payload ADC (toxin + immunomodulator) |
| Indication (IND) | Advanced solid tumors |
| Regulator action | China NMPA/CDE clinical trial notice (July 27, 2026) |
| Stage | First-in-human clinical entry |
What did Kelun-Biotech announce?
Sichuan Kelun-Biotech said it received a clinical trial notice from the Center for Drug Evaluation of China's National Medical Products Administration approving the IND for SKB565 in advanced solid tumors. The company framed the notice as its first dual-payload antibody-drug conjugate to reach the clinical stage.
Source: Kelun-Biotech's July 27 PR Newswire clinical trial notice.
How does a dual-payload ADC differ from conventional conjugates?
Conventional ADCs deliver a single cytotoxic payload. Kelun said SKB565 uses OptiDC to deliver both a toxin and an immunomodulator into tumor tissue, aiming to kill malignant cells while activating local antitumor immunity. That dual mechanism is the company's stated rationale for pursuing durability beyond toxin-only conjugates.
Whether dual payloads improve the therapeutic index in humans remains an open clinical question. Off-tumor immune activation, payload-specific toxicities, and manufacturing complexity are typical risks for this class and were not quantified in the IND notice.
What pipeline context matters for APAC desks?
Kelun-Biotech said it has more than 30 ongoing innovative projects, with four projects covering eight indications already approved for marketing and more than 10 assets in clinical stages. The company also cited two ADC projects with five indications approved and an "ADC + IO" strategy that includes combinations with PD-(L)1 antibodies and the PD-1/VEGF bispecific SKB118.
- First dual-payload ADC clinical entry for Kelun
- IND limited to advanced solid tumors (no histology specified in the release)
- Hong Kong-listed biotech (6990.HK) expanding ADC modality depth
- Builds on prior China ADC approvals rather than a first platform validation
Related China ADC and IND activity on NovaPharma includes Kelun-Harbour's SKB575 asthma IND and Hansoh Ris-Rez Phase 3 SCLC data.
What should investigators watch next?
Watch for the first-in-human protocol posting on registries such as ClinicalTrials.gov, including dose-escalation design, solid-tumor enrichment criteria, and whether immunomodulator-related cytokines are prospectively monitored. Early PK/PD should clarify whether dual payloads can be dosed without collapsing the therapeutic window.
Competitive context includes other China ADCs progressing through NMPA pathways. An IND is permission to study, not evidence of clinical benefit. Until objective response and safety tables appear, SKB565 should be tracked as a platform milestone rather than a late-stage competitor.
What remains unproven?
The release does not disclose the toxin identity, the immunomodulator identity, the antigen target, dose levels, or any human efficacy data. Preclinical "excellent antitumor activity and safety" claims cannot be independently verified from the wire alone. Global development plans outside China were not detailed.
Related NovaPharma coverage
- NMPA Clears Kelun-Harbour Asthma Bispecific IND
- Hansoh Ris-Rez Hits OS Goal in China SCLC Trial
- NMPA Approves Iza-bren for ESCC in China
Frequently Asked Questions
What IND did NMPA clear for SKB565?
On July 27, 2026, Kelun-Biotech said China's NMPA Center for Drug Evaluation issued a clinical trial notice approving the investigational new drug application for SKB565, a dual-payload ADC, in advanced solid tumors.
Why is SKB565 described as dual-payload?
Kelun said the OptiDC design delivers both a cytotoxic toxin and an immunomodulator to tumor tissue, aiming for direct killing plus local immune activation. That claim is mechanistic and still needs clinical confirmation.
Does the notice prove clinical benefit?
No. An IND or clinical trial notice authorizes human study. No patient efficacy or safety tables were released with the July 27 announcement.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for SKB565.
Unlock full calendar →Kelun-Biotech pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…